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We thank Dr Stöllberger and her colleagues for their interest in our publication. 1 This was primarily a feasibility trial of a novel device for occluding the left atrial appendage. With an experience now of over 50 patients with no major adverse events during implantation or in follow-up to 1 year, we feel that such feasibility has been demonstrated.
Dr Stöllberger et al speculate on a number of reasons that percutaneous left atrial appendage transcatheter occlusion (PLAATO) might ultimately be unsuccessful at preventing the thromboembolic complications of atrial fibrillation. Of course, the purpose of a carefully crafted clinical trial is precisely to address these and other theoretical concerns.
Though we had not seen thrombus on the device in a large series of animal studies, aspirin and clopidogrel were prescribed in the initial clinical study because of the unknown risk of thrombus formation on the device in patients with possible rheological disturbances in the setting of AF. However, we have performed serial transesophageal echocardiogram (TEEs) in our patients and have not seen any residual clot on the device surface that would lead to embolic events. Therefore, in the future, if the patient has a significant risk from these agents, a short course of clopidogrel with or without aspirin may be recommended but not required.
Dr Stollberger et al state that PLAATO is not a substitute for long-term anticoagulation treatment. We agree. Indeed, our study includes only those patients who are unable to take long-term anticoagulation therapy. At present, we would certainly advocate that patients with atrial fibrillation who are stable on anticoagulation therapy, have no major risk of bleeding, and compliant with follow up, remain on this therapy.
Few studies address the best mode of stroke prevention in patients who cannot tolerate long-term anticoagulation. Therefore, evaluating the effect of PLAATO in this cohort of patients seems appropriate. Testing the equivalency or superiority of PLAATO to warfarin in patients who are stable on warfarin would be a separate study, especially in those patients who, although stable on anticoagulation, have a strong desire to eliminate this major inconvenience from their lives. Claudia Stöllberger, Birke Schneider and Josef Finsterer
